Product Description
ACK (Activated Cdc42-associated kinase), also known as TNK2 (tyrosine kinase non-receptor 2), is a member of the non-receptor tyrosine kinase family that plays a critical role in cell migration, endocytosis, proliferation, and survival. ACK binds to and is activated by the small GTPase Cdc42, positioning it as a key signaling node linking cytoskeletal dynamics with receptor tyrosine kinase signaling pathways. Beyond its physiological functions, dysregulation of ACK signaling—including overexpression, amplification, and aberrant activation—has been implicated in various solid tumors, such as prostate, breast, lung, and glioblastoma, where it promotes tumor progression, invasion, and resistance to targeted therapies. These features have established ACK as an emerging and highly validated target for cancer therapy and drug discovery.
Screeningbio’s ACK Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying ACK kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: ACK catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the ACK kinase.
Data